Diethyl 2-methyl-2-(4-methylsulfonyloxybutyl)propanedioate | 1036708-86-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Diethyl 2-methyl-2-(4-methylsulfonyloxybutyl)propanedioate
• CAS: 1036708-86-7
• 化学式: C₁₃H₂₄O₇S
• 分子量: 324.395
• InChiKey: GZOMMVVEHVPJOD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  21
• 可旋转键数：
  12
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  104
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  Diethyl 2-methyl-2-(4-methylsulfonyloxybutyl)propanedioate 在 potassium fluoride 、 potassium carbonate 、 4,7,13,16,21,24-六氧-1,10-二氮双环[8.8.8]二十六烷 作用下， 以68%的产率得到diethyl 2-(4-fluorobutyl)-2-methylmalonate
  参考文献：
  名称：

  WO2008/81447

  摘要：

  公开号：
• 作为产物：
  描述：

  Diethyl 2-methyl-2-[4-(oxan-2-yloxy)butyl]propanedioate 在 4-甲基苯磺酸吡啶 、 三乙胺 作用下， 以 乙醇 为溶剂， 反应 1.0h， 生成 Diethyl 2-methyl-2-(4-methylsulfonyloxybutyl)propanedioate
  参考文献：
  名称：

  WO2008/81447

  摘要：

  公开号：

文献信息

• Perturbed membrane-binding compounds and methods of using the same
  申请人：ZIV Ilan

  公开号：US20080014148A1

  公开（公告）日：2008-01-17

  The present invention relates to compounds that selectively bind to cells undergoing perturbations and alterations of their normal plasma membrane organization, such as cells undergoing apoptosis or activated platelets. The invention further provides methods for utilizing said compounds in medical practice, for diagnostic and therapeutic purposes.
• Perturbed Membrane-Binding Compounds And Methods Of Using The Same
  申请人：Ziv Ilan

  公开号：US20080279774A1

  公开（公告）日：2008-11-13

  The present invention relates to compounds that selectively bind to cells undergoing perturbations and alterations of their normal plasma membrane organization, such as cells undergoing apoptosis or activated platelets. The invention further provides methods for utilizing said compounds in medical practice, for diagnostic and therapeutic purposes.
• COMPOUNDS AND METHODS FOR DETECTION OF CELLS
  申请人：Shirvan Anat

  公开号：US20100035296A1

  公开（公告）日：2010-02-11

  The invention relates to compounds comprising an ester group for the detection in vivo of cells undergoing cell death (“dying cells”) such as, for example, cells undergoing apoptosis. These compounds are selectively retained in dying cells relative to normal cells. Thus, the compounds may be used in the detection, diagnosis and treatment of clinical conditions manifested by a cell death process.
• US7270799B2
  申请人：——

  公开号：US7270799B2

  公开（公告）日：2007-09-18
• US7670590B2
  申请人：——

  公开号：US7670590B2

  公开（公告）日：2010-03-02